INTERNATIONAL CONFERENCE
on
BIOMEDICAL INNOVATION, OWNERSHIP
AND INTELLECTUAL PROPERTY-2026
Date-23rd -25th Feb 2026
Gandhi Institute of Engineering and Technology University,
Gunupur, Rayagada, Odisha – 765 022
Embedded Files
About the GIET University:
GIET University, Gunupur (formerly known as Gandhi Institute of Engineering and Technology) was established by “Vidya Bharati Educational Trust,” Gunupur, Odisha, India in the year 1997. Since inception, the Trust promotes Technical Education in India with a motto of providing Quality Education in a highly disciplined and conducive environment with International Standards. GIET University, Gunupur -A tranquil paradise, away from the noise and bustle of an urban area, surrounded by lush greenery and nestled in the beautiful foothills of eastern India. This is one of the most prestigious universities of India. It has come out as the top in eastern India because of many reasons: 26 years pioneering educational establishment and a great temple of learning, which has welcomed intellectual, cultural and social giants from the length and breadth of the country who left indelible footprints on the sands of time making GIET University a proud alma-mater. There are more than 3,780 students at GIET University, Gunupur with combination of graduates and postgraduates. High discipline: 100% ragging free environment with zero loss of working days and also 300+ top class faculty, attractive campus of 113.03 acres, incomparable infrastructure with 110 laboratories, 4 state-of-art workshop, 20 high end computer labs and 64 modern classrooms and 7 air conditioned auditoriums and best hostels having 2817 boarders of 12 boys hostel and 11 girls hostel with generator backup, Wi-Fi internet & 24hrs security system. Currently, university offers admissions to various UG, PG & Doctoral program in of various discipline and specialization like Computer Engineering, Electronics and Communication Engineering. The Institute faculty members are highly dedicated to carrying out interdisciplinary researches and design-oriented projects in line with the mission and vision of the University.
Introduction: Biomedical innovation integrates biology, medicine, engineering, and data science to develop advanced solutions for disease prevention, diagnosis, and treatment. This International conference serves as a global platform for researchers, clinicians, industry leaders, and policymakers to exchange knowledge and accelerate translational healthcare innovation and hands on training.
This revolutionary capabilities of Molecular, genetic engineering and biotechnology can revolutionize the environmental conservation, agriculture and medicine. Because of this, intellectual property (IP) rights, particularly patents, are fundamental to their development and practical use of our routine life for common public. As we know the IPR helps into incentivize and innovation by protecting investments in R&D. How IP works in these domains, raises significant questions regarding its broader implications for biodiversity, food security and public health. This International conference will examines and explore the knowledge the correlation between intellectual property rights and innovation in biotechnology and genetic engineering, highlighting key technologies such as genetically modified organisms (GMOs), CRISPR and biopharmaceuticals. It examines the challenges of patenting these recent advances in technologies, including with the monopolization of genetic resources, the inability to access life-saving medicines, and the ethical dilemmas posed by the patenting of living things in relation to sustainability. This International conferences will highlights the major discrepancies on IP governance and its implications for equitable access.
In developing nations as opposed to developed nations like US BRCA gene patent lawsuit and India's Section 3(d) pharmaceutical patent policy provide important insights into these difficulties in Indian Context. The findings of the research study state that while IPR promotes innovation, it must be balanced with public interest, or it would ultimately compromise accessibility and sustainability. Because of this, it stresses out the need for such IP frameworks to be transformed so that the creation of fair licensing policies to call for licensing of underpinned technology be established as well as the development of international treaties prioritizing sustainability and global health. To ensure that the genetic as well as the biotechnology engineering support the sustainable as well as the inclusive development, also maintaining its ethical standards, the study at the end makes a policy proposal which aligns with the IP law as well as the SDGs. Our research for the past 25 years has combined human pluripotent stem cells (hPSCs), developmental biology and engineering to model the earliest stages of cardiac development and vascularization. When I started my medical education and progressed to my training in AIIMS, New Delhi-110029, India. I envisioned growing replacement tissues in the lab and then surgically implanting them into children with congenital heart defects and birth defects and their associated diseases. Those are very rare to rare diseases.
However, after a couple of years doing hPSC research and Birth defects including with Neuro Sciences, I realized that I will be going to have to decide to be either a full-time Professor, or a full-time Research Scientist. This realization was based, in larger part, on the fact that the efficiency in differentiating Neuro Sciences and cardic sciences, cancer and birth defects research. My feeling, which aligned with the consensus in these fields that efficiency would need to be significantly increased before there was any possibility of engineering cardiac tissues, and that this foundational research would likely take several years, if not decades. Having clinical research responsibilities, in my estimation, precluded taking a deep-dive into this nascent research with so many unknowns. Subsequently, improving differentiation efficiency to over 95% creating engineered cardiac tissue took around a decade to manifest. In my opinion, we followed the advent of organoids, which, have already shown great utility in modelling developmental processes, especially the stages in human development. Recent advances bio engineering training also had a great interest in designing, building and validating tools for delivering various biophysical stimuli for perturbing hPSC fates, along with developing tools to characterize by collecting comprehensive structural and functional data, my lab and company quantifies gene expression, signalling networks and functions across different cell types at spatiotemporal scales that span several orders of magnitude, both in the engineered tissues in the Human Health.
The goal of translating organoids from academia to industry, first as a predictive platform for drug discovery in the near-term, and second, as a regenerative therapy as a long-term goal in my knowledge for research development (R&D) promotion in the Biomedical Sciences. We shall be motivating students and all the participants for starting a biotechnology research and development in our estimation, the biotechnology field has reached an inflection point where we understand key principles for controlling the research structure and function to an extent that cellular level have predictive powers. It will be assessing the drug efficacy and toxicity. As a first-time BIOTRIP-2026, the challenges will be creating a start-up have been numerous, including executing the initial mechanics of incorporating a company, identifying the most pressing unmet needs through hundreds of discussions with current end-users, decision-makers, potential partners, key opinion leaders and inventors in the field respectively. New Innovation and true in academia, creating effective strategies for fundraising and generating revenue to sustain and grow research and development (R&D) is playing an important role. The advantages of creating a start-up, new research and translation for common public is helping in (1) it forces a focus on identifying the most unmet needs in the field (2) it forces a focus on developing a minimal viable product that solves these unmet needs and (3) it creates an avenue for disseminating a technology that has the potential to improve the lives of many. Artificial Intelligence(AI) is rapidly transforming for researchers to discover, analyse, and communicate knowledge. While AI tools offer unprecedented efficiency from enhancing literature reviews to supporting data analysis and writing, they also introduce new ethical, methodological, and integrity challenges for the Research and development (R&D) for public.
Prof. (Dr.) Satya Prakash Panda
PRESIDENT
Prof. (Dr.) Chandra Dhwaj Panda
VICE PRESIDENT
Prof. (Dr.) Jagadish Panda
DIRECTOR GENERAL
Prof. (Dr.) L. M. Pattnaik
PRO CHANCELLOR
Prof. (Dr.) A.V.N.L. Sharma
VICE CHANCELLOR
Prof. (Dr.) N. V. J. Rao
REGISTRAR
Prof. (Dr.) Mayadhar Barik
DEAN, BIO MEDICAL SCIENCES
Prof. (Dr.) Brundaban Panda
ASSOCIATE PROFESSOR
Conference Overview
The International Conference on Biomedical Innovation, Ownership and Intellectual Property (ICBIOIP 2026) brings together global leaders from academia, industry, government, and international organizations to explore the evolving landscape of biomedical innovation and intellectual property (IP).As scientific breakthroughs accelerate—from genomics and AI-driven diagnostics to vaccines and personalized medicine—the questions of ownership, access, ethics, and IP governance have never been more critical. This conference provides a multidisciplinary platform to exchange ideas, present cutting-edge research, and shape future policy. Many developmental and stem cell biologists will be familiar with writing grant applications that discuss how their fundamental research findings might translate into discoveries that improve health and society, but what is really involved in this process? In this Perspective, we hear from the six researchers who have transitioned from academia to industry to help guide the development of four bioscience companies. We learn how they have navigated the opportunities and pitfalls of patents, intellectual property, investors and biotechnology start-ups to bring new biological advances from the bench and into the boardroom. Artificial Intelligence (AI) has revolutionized the biomedical sector in advanced diagnosis, treatment, and personalized medicine. While these AI-driven innovations promise vast benefits for patients and service providers, they also raise complex intellectual property (IP) challenges due to the inherent nature of AI technology. We shall be discussed the multifaceted impact of AI on IP within the biomedical sector, exploring implications in areas like drug research and discovery, personalized medicine, and medical diagnostics. We dissect critical issues surrounding AI inventorship, patent and copyright protection for AI-generated works, data ownership, and licensing. To provide context, we analysed the current IP legislative landscape in the Indian Context, highlighting convergences, divergences, and precedent-setting cases relevant to the biomedical sector. Recognizing the need for harmonization, we reviewed current developments and discussed a way forward. We advocate for a collaborative approach, convening policymakers, clinicians, researchers, industry players, legal professionals, and patient advocates to navigate this dynamic landscape. It will create a stable IP regime and unlock the full potential of AI for enhanced healthcare delivery and improved patient outcomes. This webinar provides a clear, practical framework for using AI responsibly across the research lifecycle. We will explore how to evaluate AI-generated content, prevent inaccuracies and hallucinations, ensure transparency in AI-assisted writing, safeguard sensitive data, and recognise potential bias in AI outputs. Participants will also gain insights into global guidelines from COPE, and major publishers, alongside Clarivate’s innovations in the responsible AI space. Designed for faculty, researchers, librarians, and students, the session aims to equip institutions with the awareness needed to build a culture of ethical, accountable, and trustworthy AI use in academia.
Conference Objectives
● Foster interdisciplinary collaboration in biomedical research
● Showcase cutting-edge technologies and clinical breakthroughs
● Bridge the gap between laboratory research and patient care
● Promote ethical, sustainable, and inclusive healthcare innovation
● Encourage young researchers and start-ups in biomedical sciences
Conference Themes & Tracks / Focus Area
Track 1: Biomedical Engineering & Medical Devices
● Smart implants and prosthetics
● Wearable health monitoring systems
● Robotics and automation in surgery
● Point-of-care diagnostic devices
Track 2: Artificial Intelligence & Digital Health
● AI and machine learning in medical imaging
● Clinical decision support systems
● Digital twins in personalized medicine
● Telemedicine and remote patient monitoring
● Introduction to Responsible AI in Research
● Understanding AI Capabilities and Limitations
● Ensuring Research Integrity in AI-Assisted Workflows
● Data Privacy, Security, and Sensitivity in AI Tools
● Ethical Literature Search and Review Practices
● AI-Assisted Writing: Transparency and Attribution
● Avoiding Bias and Ensuring Fairness in AI Outputs
● Using AI for Research Design and Analysis Responsibly
● Evaluating AI Tools for Trustworthiness
●
● Institutional Policies and Global Guidelines on AI Use and Building a Responsible AI Culture in Academic Institutions
Track 3: Biotechnology & Molecular Medicine
● Gene editing and CRISPR technologies
● Stem cell therapy and regenerative medicine
● Biomarkers and precision diagnostics
● Vaccine development and immunotherapy
Track 4: Digital Image Processing
● Artificial Intelligence
● Machine Learning
● Soft Computing Techniques
Track 5: Drug Discovery & Translational Research
● Computational drug design
● Nanomedicine and targeted drug delivery
● Clinical trials innovation
● From bench to bedside: translational strategies
Track 6: Bioinformatics & Systems Biology
● Multi-omics data integration
● Predictive modeling of diseases
● Big data analytics in healthcare
● Cloud computing for biomedical research
Track 7: Public Health, Ethics & Regulatory Science
● Ethical challenges in biomedical innovation
● Data privacy and cybersecurity in healthcare
● Regulatory pathways for medical products
● Global health equity and accessibility
Track 8: Graduate, Post Graduate, Research Scholar
● Paper presentation with respective fields
● Research Methodology
● Intellectual Property Right
● Innovations
● Translational Research
Track 9: Graduate, Post Graduate, Research Scholar
Advanced Molecular Biology
DNA structure and function
Gene regulation and expression
Recombinant DNA technology
Genome sequencing and bioinformatics
Cell Biology
Cell structure and organelles
Signal transduction
Cell division and apoptosis
Stem cells and regenerative biology
Biostatistics and Bioinformatics
Statistical analysis in biology
Software tools for biological data analysis (e.g., R, SPSS, Python for Bioinformatics)
Introduction to genomic data analysis
Phylogenetic trees and protein structure prediction
Biochemistry
Enzyme kinetics and mechanisms
Metabolic pathways (Glycolysis, Krebs Cycle, etc.)
Protein structure, folding, and function
Lipids and carbohydrates in cell functions
Genetics
Mendelian genetics and beyond
Molecular genetics and gene editing (CRISPR/Cas9)
Population genetics and evolution
Human genetics and genetic diseases
Microbiology
Microbial taxonomy and diversity
Host-pathogen interactions
Microbial genetics and genomics
Immunology and antimicrobial resistance
Environmental Biology
Ecology and ecosystems
Biodiversity conservation
Climate change and its biological impacts
Environmental microbiology
Research Methodology and Scientific Communication
Experimental design and techniques
Data analysis and interpretation
Writing research papers and grant proposals
Presenting scientific findings (Oral and Poster presentations)
Advanced Biotechnology
Genetic engineering and GMOs
Biotechnology applications in medicine (e.g., vaccine development)
Agricultural biotechnology
Bioreactors and industrial microbiology
Immunology
Immune system components and function
Immunodeficiencies and autoimmune diseases
Vaccine development and immunotherapies
Cancer immunology
Neurobiology
Neural signaling and neurotransmission
Brain structure and function
Neurodegenerative diseases (e.g., Alzheimer's, Parkinson's)
Neuroplasticity and learning
Bioethics and Biosafety
Ethical issues in research (e.g., cloning, genetic testing)
Clinical trials and regulatory guidelines
Biosafety in laboratories and industries
Environmental and social impacts of biotechnologies
Dissertation/Research Project
Students are expected to conduct independent research on a topic of their choice (under supervision).
Analysis, experimentation, data collection, and writing of a dissertation.
Elective Courses
Depending on the program, students can choose specialized electives, such as:
Cancer Biology
Computational Biology
Structural Biology
Marine Biology
Plant Biotechnology
Seminar Presentations
Students may be required to present their research findings in the form of seminars.
Lab Skills: Hands-on experience with PCR, Western blotting, cell culture, chromatography, etc.
Research Skills: Critical thinking, experimental design, and data analysis.
Scientific Writing and Communication: Writing papers, theses, and presenting scientific data.
Research Scientist (Academia or Industry)
Biotech/Pharmaceutical Industry Professional
Environmental Consultant
Medical Researcher
Bioinformatician
Clinical Research Coordinator
Forensic Scientist
Track 10: Graduate, Post Graduate, Research Scholar
Cell Biology & Development
🔹 Principles of Molecular Genetics / Molecular Biology
🔹 Biological/Biological Chemistry & Metabolic Regulation
🔹 Microbiology & Microbial Technology
🔹 Biostatistics / Bioanalytical Techniques
🔹 Laboratory Practical: Cell Biology, Molecular Techniques, Microbiology
👉 Focus: core biology, cells, genes, proteins, microbes, and basic lab skills.
🔹 Immunology & Immunotechniques
🔹 Recombinant DNA Technology & Genetic Engineering
🔹 Bioinformatics & Computational Biology
🔹 Plant Biotechnology / Principles of Plant Science
🔹 Practical Work: Molecular & Immunology Labs, Bioinformatics
🔹 Research Methodology basics
👉 Focus: immune systems, cutting-edge genetic tools, data analysis.
Specializations & Techniques
🔹 Animal Biotechnology
🔹 Bioprocess Engineering & Fermentation Technology
🔹 Environmental/Industrial Biotechnology
🔹 Electives (may include):
• Nanobiotechnology
• Proteomics & Genomics
• Medical/Pharmaceutical Biotechnology
• Stem Cell Biology
🔹 Practical Work & Group Project
👉 Focus: industrial applications, advanced lab & elective topics.
Advanced Topics & Research
🔹 Genomics & Proteomics
🔹 Biochemical & Biophysical Techniques
🔹 Intellectual Property Rights / Biosafety / Ethics
🔹 Dissertation / Project Work & Viva
🔹 Industrial/Research Internship
👉 Focus: specialized techniques, research experience, industry exposure.
● Advanced Cell & Molecular Biology
● Biochemistry and Enzyme Technology
● Genetics & Genetic Engineering
● Microbiology & Immunology
● Bioinformatics and Computational Biology
● Bioprocess Engineering & Fermentation
● Plant & Animal Biotechnology
● Environmental and Industrial Biotechnology
● Research Methodology & Biostatistics
● Ethics, IPR & Biosafety
● Hands-on Laboratory Techniques
🧪 Practical & Research Emphasis
Biotechnology master’s programs have a strong lab component, including experiments on:
● DNA/ RNA isolation, PCR, gene cloning
● Protein purification & enzyme assays
● Cell & tissue culture
● Bioinformatics software and sequence analysis
● Bioprocessing experiments
👉 Final projects and internships are often part of all Semester .
Drug design, synthetic biology, medical biotech, etc.
` Keynote Topics (Sample)
● The Future of Precision Medicine
● AI-Driven Healthcare: Opportunities and Risks
● Innovations in Regenerative Medicine
● Biomedical Innovation for Sustainable Healthcare Systems
● Biomedical Engineering
● Science and Technology
● Engineering and Technology
● Pharmacy
● Nursing
● Medicine
● Surgery
Workshops & Special Sessions
● Hands-on workshop on AI tools for biomedical research
● Startup and industry-academia collaboration forum
● Grant writing and funding opportunities in biomedical science
● Young Researchers and PhD Colloquium
Paper Presentation & Publication
● Original research papers
● Review articles and case studies
● Clinical and industrial innovations
● Accepted papers published in reputed indexed journals / conference proceedings
Target Participants
● Biomedical researchers and scientists
● Medical professionals and clinicians
● Engineers and technologists
● Industry experts and entrepreneurs
● Policymakers and regulatory authorities
● Graduate students and early-career researchers
Expected Outcomes
● Knowledge exchange and global networking
● Research collaborations and partnerships
● Translation of innovation into clinical practice
● Policy and regulatory insights
● Empowerment of emerging biomedical innovators
🔬 Biomedical Innovation
● Translational research and commercialization
● Emerging technologies in biotechnology and healthcare
● AI, genomics, and digital health innovations
⚖️ Intellectual Property & Law
● Patent systems in biotechnology and pharmaceuticals
● Trade secrets, data exclusivity, and regulatory protection
● International IP frameworks (TRIPS, WIPO, WTO)
🌍 Ownership, Ethics & Access
● Ownership of genetic data and biological materials
● Equity, access to medicines, and global health justice
● Ethical challenges in biomedical IP
🏭 Industry & Technology Transfer
● University–industry collaboration
● Licensing, startups, and spin-offs
● Valuation and management of biomedical IP
📜 Policy & Governance
● Public-private partnerships
● Innovation policy and global health emergencies
● IP reform for sustainable innovation
NB: This track is a general syllabus, and depending on your focus (such as in microbiology, molecular biology, or bioinformatics), the subjects may differ. Some programs may also offer opportunities for internships or industry collaborations as part of the curriculum.
Host Organization(s):
Gandhi Institute of Engineering and Technology University, Gunupur, Rayagada, Odisha – 765 022
Dates & Venue (physical / virtual / hybrid): Date-22nd -25nd Feb,Gandhi Institute of Engineering and Technology University, Gunupur, Rayagada, Odisha – 765 022
Official Language(s): English and Hindi
Target Audience (academics, industry, policymakers, students): 10000
Keynote Speakers (Tentative)
● Prof. Maria Sanchez, Global Health Law, WHO
● Dr. Alan Robertson, Chief Innovation Officer, BioTech Global
● Prof. Li Wei, Intellectual Property & Biotechnology, Tsinghua University
● Dr. Amina El-Sayed, Ethics of Biomedical Innovation, UNESCO
● Prof. Ashan Rizvi, USA
● Prof. Anupama Numbru, JNU
Who Should Attend
● Researchers & Academicians
● Biomedical & Pharmaceutical Professionals
● IP Lawyers & Patent Agents
● Policymakers & Regulators
● Technology Transfer Officers
● Startup Founders & Investors
● Postgraduate & Doctoral Students
● BTec. MTech,, BSc. Nursing, MSc. Nursing
● Pharmacy, MBBS, MD, BDS,MDS and Paramedical Sciences
● All disciplines of Engineering and Technology
Call for Papers
We invite original research papers, case studies, policy analyses, and review papers related to the conference themes.
Call for Paper Started: 14 February 2026
📌 Submission Deadline: 18 February 2026
📌 Notification of Acceptance: 20 February l 2026
📌 Camera-Ready Submission: 21 February 2026
✔ Selected papers will be published in indexed conference proceedings and partner journals/Text Book.
Conference Highlights
✨ Keynote & Plenary Sessions
✨ Panel Discussions with Global Experts
✨ Paper & Poster Presentations
✨ IP & Innovation Workshops
✨ Networking & Collaboration Sessions
✨ Best Paper & Young Researcher Awards
Registration Categories
Category
Early Bird Regular Indian
Academicians/Professionals USD 350 USD 450 3000.00
Students/Research Scholars USD 200 USD 300 2000.00
Virtual Participants USD 200 USD 300 2000.00
Organizational Structure
● Patron / Chief Guest
● Conference Chair / Co-Chair
● Organizing Committee
● Scientific / Technical Committee
● Advisory Board
● Review Committee
Be part of a global dialogue shaping the future of biomedical innovation, ownership, and intellectual property—where science meets law, ethics, and society.
🌍 Innovate. Protect. Share and Hands on.
Just tell me the purpose and audience.
Program Structure
Day-wise Format (Typical)
Inaugural Session
● Welcome Address
● Opening Remarks
● Keynote Address
● Guest of Honor Speech
● Conference Overview
Technical Sessions
● Oral Presentations
● Parallel Sessions / Tracks
● Panel Discussions
● Workshops / Tutorials
Poster Sessions
● Scheduled viewing time
● Presenter interaction
Plenary / Keynote Sessions
● Renowned international speakers
● Cross-disciplinary topics
Special Sessions
● Industry–Academia Meet
● Roundtable Discussions
● Student Research Forum
Valedictory / Closing Session
● Summary of outcomes
● Awards & Certificates
● Vote of Thanks
Paper & Presentation Format
Paper Submission as per the standard given below:
● Abstract (200–300 words)
● Full Paper (6–10 pages)
● Standard Templates (IEEE / Springer / ACM, etc.)
● Peer-review process (single-blind / double-blind)
Presentation
● Oral: 10–15 min presentation + Q&A
● Poster: A0 or A1 size (or digital posters for virtual)
Registration Structure
● Early Bird / Regular / Late Registration
● Categories:
o International Delegates
o Domestic Delegates
o Students / Research Scholars
o Industry Participants
Proceedings & Publications
● ISBN/ISSN Proceedings
● Indexed Journals (Scopus / Web of Science, if applicable)
● Digital Library Access
Networking & Cultural Elements
● Welcome Reception
● Conference Dinner / Cultural Program
● Exhibition / Sponsor Booths
● Networking Breaks
Virtual / Hybrid Conference Additions
● Time-zone adjusted schedule
● Live streaming & recordings
● Online Q&A & chat rooms
● Virtual poster halls
Conclusion/Outcome:
The International Conference on Biomedical Innovation, Ownership and Intellectual Property (ICBIOIP 2026) aims to shape the future of healthcare by fostering collaboration across disciplines and borders. By uniting innovation, ethics, and technology, the conference contributes to improving global health outcomes. we participate in the entire spectrum of translational research, but our focus is in the areas of basic research and new methods to prevent, diagnose, and treat disease, extending to proof of concept preclinical and Phase 1 studies. Since we believe that all phases of translational research should have an equity lens, we have instituted an initiative to encourage thought and planning about global equitable access to discoveries made by our trainee Clinical Scholars and faculty, even at the earliest phases of basic research. Assuring global equitable access to new technologies requires addressing at least 3 different aspects of new technology: Patenting and licensing, Manufacturing, and Dissemination and implementation in low- and middle-income countries. In this review, I focus on patenting and licensing and offer ten questions for inventors to consider in discussing licensing their technologies with technology transfer officers to maximize equitable global access to the technologies they create. The framework offers a structured and systematic approach for identifying data on public and philanthropic contributions to developing medical products (medicines and devices). This information is often not comprehensively documented. Therefore, aligned public policies enforcing transparent and standardized reporting in sufficient granularity on R&D investments and conditions are key. This International Conferences addresses the question of the possibility of medical research without patents, a major issue in healthcare research and policy. We discuss and evaluate the relevant scientific, economic, societal, and moral aspects of our system of funding and organizing the research, development, manufacture and sale of prescription drugs. The focus is on the patent practices of big pharmaceutical companies. We analyze and critically assess the main features and impacts of these practices. In a positive sense, we propose an approach to organizing and funding drug research that prioritizes its public interest rather than its privatization through patenting. For these purposes, we first demonstrate that producing prescription drugs through patenting has serious drawbacks. Second, we develop a concrete alternative (medical research without patents) that is shown to be scientifically, socially and morally preferable, economically and financially profitable, and socio-politically and organizationally practicable.
Contact:
Prof. (Dr.) Mayadhar Barik, AIIMS, Sir APJ Abdul Kalam, Tejaswini & Excellence in Research Awardee , Convenor & Advisor BIOTRIP-2026,
Dean R&D, BioMedical Sciences, GIET University, Gunupur-765022, Odisha, India
Email: biotripgietu@gmail.com,
📞 Phone: +91-70 0892 3339
Report abuse